Fujifilm Biotechnologies opened an expanded Teesside campus in the UK backed by roughly £400 million ($545 million), unveiling what the company calls the UK’s largest single-use biopharma CDMO. The 110,000 sq. ft. manufacturing footprint adds 2,000 L and 5,000 L single-use bioreactors and total flexible capacity up to 19,000 L, with an operational target in H1 2026. The expansion also launches the Bioprocess Innovation Centre UK (BIC UK), a 102,200 sq. ft. lab hub for high-throughput and continuous process development intended to accelerate tech transfer across Fujifilm’s global network. Fujifilm executives highlighted the kojoX modular approach to harmonize equipment and processes across sites in Japan and the UK. Clarification: A CDMO (contract development and manufacturing organization) provides outsourced biologics manufacturing and process development services to biopharma sponsors.